OTLK – outlook therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock.
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $1.00 price target on the stock.
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Form 8-K Outlook Therapeutics, For: Feb 18
Form 10-Q Outlook Therapeutics, For: Dec 31
Form 8-K Outlook Therapeutics, For: Feb 17
Form 8-K Outlook Therapeutics, For: Feb 11
Form SCHEDULE 13G/A Outlook Therapeutics, Filed by: SPHERA FUNDS MANAGEMENT LTD.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.